Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of the endocannabinoid system in diabetes and diabetic complications
Gabriella Gruden, Federica Barutta, George Kunos, et al.
British Journal of Pharmacology (2015) Vol. 173, Iss. 7, pp. 1116-1127
Open Access | Times Cited: 137

Showing 1-25 of 137 citing articles:

New approaches and challenges to targeting the endocannabinoid system
Vincenzo Di Marzo
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 9, pp. 623-639
Closed Access | Times Cited: 412
Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly
Pál Pacher, Sabine Steffens, György Haskó, et al.
Nature Reviews Cardiology (2017) Vol. 15, Iss. 3, pp. 151-166
Closed Access | Times Cited: 358
Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity
Marjolein Soethoudt, Uwe Grether, Jürgen Fingerle, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 305
Bioactive lipids, inflammation and chronic diseases
Alessandro Leuti, Domenico Fazio, Marina Fava, et al.
Advanced Drug Delivery Reviews (2020) Vol. 159, pp. 133-169
Closed Access | Times Cited: 234
The links between sleep duration, obesity and type 2 diabetes mellitus
Christina Antza, Georgios Kostopoulos, Samiul Mostafa, et al.
Journal of Endocrinology (2021) Vol. 252, Iss. 2, pp. 125-141
Open Access | Times Cited: 178
Mechanisms of podocyte injury and implications for diabetic nephropathy
Federica Barutta, Stefania Bellini, Gabriella Gruden
Clinical Science (2022) Vol. 136, Iss. 7, pp. 493-520
Open Access | Times Cited: 115
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Mauro Maccarrone, Vincenzo Di Marzo, Jürg Gertsch, et al.
Pharmacological Reviews (2023) Vol. 75, Iss. 5, pp. 885-958
Open Access | Times Cited: 83
Ferroptosis as a Novel Therapeutic Target for Diabetes and Its Complications
Xi‐Ding Yang, Yong‐Yu Yang
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 75
Beyond THC and Endocannabinoids
Pál Pacher, Natalya M. Kogan, Raphael Mechoulam
The Annual Review of Pharmacology and Toxicology (2019) Vol. 60, Iss. 1, pp. 637-659
Closed Access | Times Cited: 143
G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus
Darren Riddy, Philippe Delerive, Roger J. Summers, et al.
Pharmacological Reviews (2017) Vol. 70, Iss. 1, pp. 39-67
Open Access | Times Cited: 102
A Guide to Targeting the Endocannabinoid System in Drug Design
Adam Stasiulewicz, Katarzyna Znajdek, Monika Grudzień, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 8, pp. 2778-2778
Open Access | Times Cited: 102
Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation
János Pálóczi, Zoltán V. Varga, George Hasko, et al.
Antioxidants and Redox Signaling (2017) Vol. 29, Iss. 1, pp. 75-108
Open Access | Times Cited: 97
Modulation of the Oxidative Stress and Lipid Peroxidation by Endocannabinoids and Their Lipid Analogues
Cristina Anna Gallelli, Silvio Calcagnini, Adele Romano, et al.
Antioxidants (2018) Vol. 7, Iss. 7, pp. 93-93
Open Access | Times Cited: 89
Role of Cannabinoids in Obesity
Francesca Rossi, Francesca Punzo, Giuseppina Rosaria Umano, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 9, pp. 2690-2690
Open Access | Times Cited: 85
The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus
Alain Veilleux, Vincenzo Di Marzo, Cristoforo Silvestri
Current Diabetes Reports (2019) Vol. 19, Iss. 11
Open Access | Times Cited: 78
Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol
Patrycja Bielawiec, Ewa Harasim‐Symbor, Adrian Chabowski
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 75
Benzimidazoles in Drug Discovery: A Patent Review
Christine Shing Wei Law, Keng Yoon Yeong
ChemMedChem (2021) Vol. 16, Iss. 12, pp. 1861-1877
Closed Access | Times Cited: 64
A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of β-caryophyllene, a dietary cannabinoid
Hebaallah Mamdouh Hashiesh, Charu Sharma, Sameer N. Goyal, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 140, pp. 111639-111639
Open Access | Times Cited: 56
Intestinal Barrier Function and Immune Homeostasis Are Missing Links in Obesity and Type 2 Diabetes Development
Sylvia Riedel, Carmen Pheiffer, Rabia Johnson, et al.
Frontiers in Endocrinology (2022) Vol. 12
Open Access | Times Cited: 44
Combination treatment with FAAH inhibitors/URB597 and ferroptosis inducers significantly decreases the growth and metastasis of renal cell carcinoma cells via the PI3K-AKT signaling pathway
Junfeng Hao, Qiguang Chen, Yongmin Feng, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 4
Open Access | Times Cited: 23
Therapeutic applications of cannabinoids
Nancy Maurya, Bharath Kumar Velmurugan
Chemico-Biological Interactions (2018) Vol. 293, pp. 77-88
Closed Access | Times Cited: 69
The gut microbiome, endocannabinoids and metabolic disorders
Fabio Arturo Iannotti, Vincenzo Di Marzo
Journal of Endocrinology (2020) Vol. 248, Iss. 2, pp. R83-R97
Open Access | Times Cited: 64
The role of cannabinoid signaling in acute and chronic kidney diseases
Federica Barutta, Graziella Bruno, Raffaella Mastrocola, et al.
Kidney International (2018) Vol. 94, Iss. 2, pp. 252-258
Closed Access | Times Cited: 61
Targeted inhibition of the type 2 cannabinoid receptor is a novel approach to reduce renal fibrosis
Lili Zhou, Shan Zhou, Peng Yang, et al.
Kidney International (2018) Vol. 94, Iss. 4, pp. 756-772
Open Access | Times Cited: 61
Chronic Cannabidiol Administration Fails to Diminish Blood Pressure in Rats with Primary and Secondary Hypertension Despite Its Effects on Cardiac and Plasma Endocannabinoid System, Oxidative Stress and Lipid Metabolism
Patryk Remiszewski, Iwona Jarocka-Karpowicz, Michał Biernacki, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 4, pp. 1295-1295
Open Access | Times Cited: 54
Page 1 - Next Page

Scroll to top